Compare DSP & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | BNR |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.1M | 216.9M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | BNR |
|---|---|---|
| Price | $11.36 | $22.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $18.50 | N/A |
| AVG Volume (30 Days) | ★ 219.1K | 52.5K |
| Earning Date | 11-10-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $324,131,000.00 | $75,749,382.00 |
| Revenue This Year | $17.79 | $136.32 |
| Revenue Next Year | $17.72 | N/A |
| P/E Ratio | $115.77 | ★ N/A |
| Revenue Growth | ★ 22.97 | 5.56 |
| 52 Week Low | $8.11 | $2.18 |
| 52 Week High | $26.33 | $24.92 |
| Indicator | DSP | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 48.43 | 58.46 |
| Support Level | $11.42 | $19.10 |
| Resistance Level | $12.20 | $23.52 |
| Average True Range (ATR) | 0.39 | 2.33 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 13.04 | 71.22 |
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.